Alem Truneh on 21-Jul-1995 12:08

To: Mark R Hurle
cc:
Subject: Proposed HGS Collaborations (MTA #'s 166, 168, 172 and 173)

To: Patricia M Dormer
cc: Gordon P Moore
Andrew J Nichols
John C Lee
Peter R Young
Kong B Tan
From: Alem Truneh Phone: x4884 Fax: x6186
Date: 19-Jul-95 08:14:32 AM
Subject: Proposed HGS Collaborations (MTA #'s 166, 168, 172 and 173)
Categories: ATG Management

With respect to the proposals listed below on TNF-related molecules, we would like a number of this proposals to be rejected for the following reasons.

1) There is currently a very active interest on TNF/TNFR-related molecules. A number of departments have already indicated their strong interest and some have already committed resources to work in this area. They include:

* Molecular Immunology
* Cellular Biochemistry
* Respiratory Pharmacology
* Macromolecular Sciences
* Gene Expression Sciences

2) A Working Party has already been formed comprising members from all the above departments. Members of this Team have already had one meeting on this subject with HGS on March 29 , 1995, and two meetings of SB members only on April 21, 1995 and July 10, 1995, to lay out plans and discuss progress (minutes of the July 10, 1995 meeting will be issued shortly). Regular joint SB/HGS meetings are under discussion.

3) A number of work requests have been submitted to HGS on TNF/TNFR-related novel genes, from several departments, including second walks, full sequences and requests of clones. A recompiled list of work requests is attached with this document (Excel spreadsheet).

TNF_TNFR.XLS

Alem Truneh on 21-Jul-1995 12:08

To: Mark R Hurle
cc:
Subject: Proposed HGS Collaborations (MTA #'s 166, 168, 172 and 173)

To: Patricia M Dormer
cc: Gordon P Moore
Andrew J Nichols
John C Lee
Peter R Young
Kong B Tan
From: Alem Truneh Phone: x4884 Fax: x6186
Date: 19-Jul-95 08:14:32 AM
Subject: Proposed HGS Collaborations (MTA #'s 166, 168, 172 and 173)
Categories: ATG Management

With respect to the proposals listed below on TNF-related molecules, we would like a number of this proposals to be rejected for the following reasons.

1) There is currently a very active interest on TNF/TNFR-related molecules. A number of departments have already indicated their strong interest and some have already committed resources to work in this area. They include:
* Molecular Immunology
* Cellular Biochemistry
* Respiratory Pharmacology
* Macromolecular Sciences
* Gene Expression Sciences

2) A Working Party has already been formed comprising members from all the above departments. Members of this Team have already had one meeting on this subject with HGS on March 29 , 1995, and two meetings of SB members only on April 21, 1995 and July 10, 1995, to lay out plans and discuss progress (minutes of the July 10, 1995 meeting will be issued shortly). Regular joint SB/HGS meetings are under discussion.

3) A number of work requests have been submitted to HGS on TNF/TNFR-related novel genes, from several departments, including second walks, full sequences and requests of clones. A recompiled list of work requests is attached with this document (Excel spreadsheet).

TNF_TNFR.XLS

4) Immediate and future plans for the team include:
* Determine tissue distribution of all putative novel TNF/TNFR-related gene products by Northern analysis and in situ hybridization (already initiated)
* express the ligands and receptors as soluble proteins (already initiated)
* generate antisera using peptides derived from these sequences (already initiated)
* generate monoclonal antibodies (mAbs) (planning already underway)
* conduct immunohistochemical analysis using reagents generated as above (future)
* determine binding reactivities of the ligands and receptors (planned)
* determine effect of soluble ligands and receptors as well as mAbs on in vitro functional assays in the immune, hematopoietic and host defense systems (to be conducted after generation of above reagents)
* determine the signalling function of these molecules (planned)
* identify receptor-ligand pairs for these molecules (future)
* determine ways to conduct tests in animal models (future)

5) In terms of therapeutic approaches, the "Working Party" plans to determine the utility, as protein agents, of the soluble ligands and receptors as well as mAbs to this targets. In the long term, other approaches will be considered.

6) Among the genes that you listed, there is less activity with the TRAF-related genes. If there is a strong desire at HGS to establish external collaboration on the TRAF-related genes, there is less of a concern among the SB scientists in this "Working Party" for direct overlap (or conflict) of activities, although all scientist have indicated a strong desire for direct and regular access to information generated through these collaborations, preferably through direct contact with the relevant outside investigator.
This genes are:
232058 TRAF
417837 TRAF
187343 TRAF

Please let me know if you need any further information.
Regards,
Alem.

To: Alem Truneh
cc: Gordon P Moore
Andrew J Nichols
From: Patricia M Dormer ext. 3720, FF0405
Date: 18-Jul-95 09:00:14 AM
Subject: Proposed HGS Collaborations (MTA #'s 166, 168, 172 and 173)
Categories:

Alem,

I have not received any information from the group which is working with TNF which proves the following proposed HGS-MTAs would significantly overlap work ongoing at SB:

HGS-MTA	Clones	Gene Application/Indication
166	103902	TNF
	250630	TNF
	232058	TRAF
	417837	TRAF
	187343	TRAF
168	32629	chemotactic cytokine
172	250630	TNF-γ as an Inhibitor of Hepatitis Virus
173	80245	TNF
	250630	TNF

Also, I have reviewed the Use of HGS Materials Database to see if the entries for clones 103902 and 250630 have been updated to show ongoing work at SB; neither entry has been changed.

If the necessary information is not received prior to the MTA Committee Meeting on Thursday July 20, these MTAs will be approved.

Regards,

Trish